Find out more about us and our portfolio companies

Oversubscribed £50m Series B led by SV Health Investors’ Dementia Discovery Fund, alongside other new investors British Business Bank, M Ventures, Novartis Venture Fund and Criteria Bio Ventures, together with existing investors Omega Funds and Brandon Capital. 

The financing will enable NRG Therapeutics to deliver clinical proof of concept in ALS/MND with NRG5051, a first-in-class, oral inhibitor of the mitochondrial permeability transition pore (mPTP).

The mPTP is a well-established driver of mitochondrial dysfunction, inflammation, and neuronal death in neurodegenerative diseases. NRG’s pipeline of small molecules inhibit pore opening through a novel mechanism of action. 

Polaris, a leading developer of next-generation optical modulators for bandwidth- and power-constrained interconnects, announces their Series A funding round and the appointment of a new CEO to drive commercialization.